Loading stock data…
PAVM
$6.31-0.05 (-0.79%)
PAVmed Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PAVmed Inc. in the Healthcare sector is trading at $6.31. Wall Street consensus targets $40.50 (2 analysts), implying a +541.8% move over the next 12 months. The stock is currently near its 52-week low of $6.00, remaining 42.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +541.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 20) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$6.31
Potential Downside
0%
Whystock Fair Value$6.31
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$40.50+541.8%
Range$16.00 – $65.00
Fundamentals
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for u...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$59.17M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-252.42%
Volume
Today's trading volume
11,164
Recent News
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates
Microbot Medical (MBOT) delivered earnings and revenue surprises of +37.50% and -76.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of +32.75% and +2.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Will PAVmed Inc. (PAVM) Report Negative Earnings Next Week? What You Should Know
PAVmed (PAVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alphatec (ATEC) Reports Break-Even Earnings for Q1
Alphatec (ATEC) delivered earnings and revenue surprises of +100.00% and -3.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BIOROBO (PRCT) delivered earnings and revenue surprises of -2.43% and +3.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?